Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase IB/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, And Efficacy of Mosunetuzumab BTCT4465a In Combination with Chop or CHP-Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma
Study Type: Treatment
Phase: I/II
NCTID: NCT03677141
Principal Investigator:
Marc Hoffmann
A Phase III, Multicenter, Randomized, Open-Label Trial to Evaluate Efficacy and Safety of Ribociclib with Endocrine Therapy as An Adjuvant Treatment in Patients with Hormone Receptor-Positive, HER2-Negative, Early Breast Cancer New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE
A Randomized, Double-Blind, Placebo-Controlled Study of the Pi3K Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
Phase I/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
Study Type: Treatment
Phase: I
NCTID: NCT05627245
Principal Investigator:
Aung Tun
A Phase IB Trial of Neoadjuvant AMG 232 Concurrent With Preoperative Radiotherapy in Wild-Type p53 Soft Tissue Sarcoma STS
Study Type: Treatment
Phase: I
NCTID: NCT03217266
Principal Investigator:
Benjamin Powers
A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 Daunorubicin and Cytarabine Liposome for Injection Treatment in Adult Patients with Hematologic Malignancies
Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without M7824 bintrafusp alfa as First-line Treatment of Biliary Tract Cancer
A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma
Study Type: Treatment
Phase: II
NCTID: NCT06050252
Principal Investigator:
Raed Al-Rajabi